GlassScriptPhysician profile
Stacy Lynn Terry
NPI 1417921008
$2,669.09
in general payments reported to CMS, 2019-2025
25 companies · $238 in 2025
The $238 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $417 · 2021: $307 · 2022: $524 · 2023: $489 · 2024: $337 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $538.50 | 2021-2025 | Azstarys |
| Tris Pharma INC | $428.13 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Ironshore Pharmaceuticals INC. | $386.80 | 2019-2024 | Jornay Pm |
| Cranial Technologies, INC | $183.74 | 2019-2024 | Doc Band |
| Sanofi Pasteur INC. | $163.17 | 2021-2025 | |
| Neos Therapeutics, LP | $139.09 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.21 | 2020-2022 | |
| Pacira Pharmaceuticals Incorporated | $106.24 | 2019 | |
| Adlon Therapeutics L.P. | $90.09 | 2020-2021 | |
| Pfizer INC. | $79.64 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $66.02 | 2021-2024 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $62.91 | 2019-2021 | |
| Sobi, INC | $59.00 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $41.16 | 2024 | |
| Shire North American Group INC | $32.09 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $31.24 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $23.35 | 2023 | Flumist Quadrivalent |
| Mayne Pharma Commercial LLC | $21.45 | 2023 | |
| Nestle Healthcare Nutrition INC. | $17.99 | 2023 | |
| Dermira, INC. | $16.18 | 2020 | |
| Alk-Abello, INC | $15.84 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $14.99 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.94 | 2025 | Zoryve |
| Genentech USA, INC. | $13.83 | 2019 | |
| Merck Sharp & Dohme LLC | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Terry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.